SCHEMBL27201480

SCHEMBL27201480

CN1CCN(C(=O)c2cccc(-c3ccc4ccnc(N)c4c3)c2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.56
KDM4E B2RXH2 1/20 0.56
ERN1 O75460 2/20 0.55
FYN P06241 1/20 0.54
ADORA2A P29274 1/20 0.53
ATR Q13535 1/20 0.52
PIK3CD O00329 4/20 0.52
PIK3CA P42336 4/20 0.52
KCNH2 Q12809 4/20 0.52
MTOR P42345 1/20 0.52
PIK3CB P42338 3/20 0.52
PIK3CG P48736 3/20 0.52
MAP4K4 O95819 1/20 0.50
SLC6A7 Q99884 1/20 0.48
HPGD P15428 1/20 0.48
TSHR P16473 1/20 0.48
POLB P06746 1/20 0.47
C1S P09871 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30885229 1.00 L3MBTL1 (0.56) L3MBTL1KDM4EERN1FYNADORA2A
SCHEMBL30885245 0.90 ERN1 (0.52) ERN1ADORA2AATRMTORSLC6A7
SCHEMBL27201415 0.90 ERN1 (0.52) ERN1ADORA2AATRMTORSLC6A7
SCHEMBL30834193 0.85 HPGD (0.51) FYNATRPIK3CDPIK3CAKCNH2
SCHEMBL27201335 0.85 HPGD (0.51) FYNATRPIK3CDPIK3CAKCNH2
SCHEMBL27201434 0.81 ATR (0.57) ATRMAP4K4
SCHEMBL30834177 0.81 ATR (0.57) ATRMAP4K4
SCHEMBL27201638 0.79 MAP4K4 (0.50) ERN1ATRMAP4K4
SCHEMBL27201518 0.77 CA12 (0.51) ERN1
SCHEMBL13618033 0.76 L3MBTL1 (0.61) L3MBTL1KDM4EERN1FYNADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US claimed
WO-2024073502-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-04 WO claimed
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP L3MBTL1 469/4885KDM4E 1293/4885ERN1 1734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.